140 related articles for article (PubMed ID: 12236319)
1. Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) Study.
Saito Y; Shirai K; Sasaki N; Shinomiya M; Yoshida S;
J Atheroscler Thromb; 2002; 9(2):99-108. PubMed ID: 12236319
[TBL] [Abstract][Full Text] [Related]
2. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
[TBL] [Abstract][Full Text] [Related]
3. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events.
Pfeffer MA; Sacks FM; Moyé LA; East C; Goldman S; Nash DT; Rouleau JR; Rouleau JL; Sussex BA; Theroux P; Vanden Belt RJ; Braunwald E
J Am Coll Cardiol; 1999 Jan; 33(1):125-30. PubMed ID: 9935018
[TBL] [Abstract][Full Text] [Related]
4. [Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study].
Arntz HR; Wunderlich W; Schnitzer L; Stern R; Fischer F; Agrawal R; Linderer T; Schultheiss HP
Z Kardiol; 1999 Aug; 88(8):582-90. PubMed ID: 10506395
[TBL] [Abstract][Full Text] [Related]
5. Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: Hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT).
Koizumi J; Shimizu M; Miyamoto S; Origasa H; Mabuchi H
J Atheroscler Thromb; 2002; 9(5):251-9. PubMed ID: 12409635
[TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
[TBL] [Abstract][Full Text] [Related]
7. Pravastatin use and risk of coronary events and cerebral infarction in japanese men with moderate hypercholesterolemia: the Kyushu Lipid Intervention Study.
J Atheroscler Thromb; 2000; 7(2):110-21. PubMed ID: 11426582
[TBL] [Abstract][Full Text] [Related]
8. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE).
Ito H; Ouchi Y; Ohashi Y; Saito Y; Ishikawa T; Nakamura H; Orimo H
J Atheroscler Thromb; 2001; 8(2):33-44. PubMed ID: 11770708
[TBL] [Abstract][Full Text] [Related]
9. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
[TBL] [Abstract][Full Text] [Related]
10. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Ridker PM; Morrow DA; Rose LM; Rifai N; Cannon CP; Braunwald E
J Am Coll Cardiol; 2005 May; 45(10):1644-8. PubMed ID: 15893181
[TBL] [Abstract][Full Text] [Related]
11. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
Shepherd J; Cobbe SM; Ford I; Isles CG; Lorimer AR; MacFarlane PW; McKillop JH; Packard CJ
N Engl J Med; 1995 Nov; 333(20):1301-7. PubMed ID: 7566020
[TBL] [Abstract][Full Text] [Related]
12. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
13. [Pravastatin in patients with cardiac risk factors. Effects of pravastatin in patients with total serum cholesterol concentrations of 200 to 300 mg/dl (5.2 to 7.8 mmol/l) and two additional atherosclerosis risk factors. Pravastatin Multinational Study Group for Cardiac Risk Patients].
Fortschr Med; 1994 Feb; 112(5):57-64. PubMed ID: 8163252
[TBL] [Abstract][Full Text] [Related]
14. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
[TBL] [Abstract][Full Text] [Related]
15. Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico).
Ital Heart J; 2000 Dec; 1(12):810-20. PubMed ID: 11302109
[TBL] [Abstract][Full Text] [Related]
16. Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness.
McPherson R; Hanna K; Agro A; Braeken A;
Clin Ther; 2001 Sep; 23(9):1492-507. PubMed ID: 11589262
[TBL] [Abstract][Full Text] [Related]
17. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients.
Am J Cardiol; 1993 Nov; 72(14):1031-7. PubMed ID: 8213583
[TBL] [Abstract][Full Text] [Related]
18. Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.
Nakamura H;
Atheroscler Suppl; 2007 Aug; 8(2):13-7. PubMed ID: 17586102
[TBL] [Abstract][Full Text] [Related]
19. A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group.
J Atheroscler Thromb; 1996; 3(2):95-104. PubMed ID: 9226461
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.
Goldberg RB; Mellies MJ; Sacks FM; Moyé LA; Howard BV; Howard WJ; Davis BR; Cole TG; Pfeffer MA; Braunwald E
Circulation; 1998 Dec; 98(23):2513-9. PubMed ID: 9843456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
